Nektar Therapeutics (NKTR) AI Stock Analysis

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for critical unmet medical needs. Its pipeline includes Bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist in Phase 3 trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma. The company is also evaluating NKTR-358 in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, alongside NKTR-255 in Phase 1/2 studies for oncology indications including non-Hodgkin's lymphoma and colorectal cancer. Nektar collaborates with partners such as Takeda, AstraZeneca, Roche, Pfizer, Amgen, and Bristol-Myers Squibb.

Nektar Therapeutics saw annual revenue decline from $101.9M in FY2021 to $92.1M in FY2022 and $90.1M in FY2023. While revenue rebounded 9.2% in FY2024 to $98.4M, it dropped 43.9% to $55.2M in FY2025, yielding a 5-year revenue CAGR of -18.4% from FY2020 to FY2025. Gross margin reached 100.0% in FY2025, but operating margin remained negative at -236.8%, resulting in an FY2025 net income of -$164.1M and EPS of -$10.21. For the trailing twelve months ended June 30, 2026, revenue stood at $54.6M with a profit margin of -287.8%, while latest quarterly revenue fell 9.3% year-over-year.

As of June 30, 2026, Nektar held $684.3M in cash and short-term investments against total debt of $135.9M, establishing a net cash position of $548.4M. The company maintains liquidity with a current ratio of 10.42 and a debt-to-equity ratio of 0.15. In FY2025, operating cash flow was -$208.5M, free cash flow was -$208.7M, and capital expenditures were $171,000. Additionally, the share count expanded 168.1% over the past 5 years.

At a closing price of $35.78 on October 16, 2026, Nektar has a market cap of $1.22B and an enterprise value of $1.36B. The stock trades at a forward P/E of 34.0x, above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales ratio is 22.4x, well above the peer median of 4.1x, with a price-to-book of 2.2x. Over the past year, NKTR shares dropped 34.9%, underperforming the 16.8% gain for the S&P 500. Over 5 years, the stock returned -86.2% compared to an 83.0% return for the benchmark.

Wall Street analysts hold 10 Strong Buy, 1 Buy, and 4 Hold ratings on Nektar, with no Sell recommendations. The mean price target of $133.08 sits 271.9% above the last close of $35.78. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$8.08 on revenue of $41.8M. For the following fiscal year, 15 analysts expect revenue of $53.4M and EPS of -$10.50. Nektar has beaten EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 5, 2026.

This page is an AI-written research summary of Nektar Therapeutics (NKTR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NKTR income statement, NKTR balance sheet, NKTR key metrics, NKTR analyst forecast, NKTR chart. See the NKTR stock overview for the latest quote and news.